{"id":135,"date":"2023-01-24T10:00:00","date_gmt":"2023-01-24T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=135"},"modified":"2025-09-02T01:36:21","modified_gmt":"2025-09-02T01:36:21","slug":"china-bd-2023-hutchmed-and-takeda-enters-a-1-13-billion-usd-license-on-vegfr-tki-fruquintinib","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/135.html","title":{"rendered":"[China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI\u00a0Fruquintinib"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<p>Announced Date: 2023-01-23 (January 23, 2023)<\/p>\n\n\n\n<p>Asset Name: Fruquintinib<\/p>\n\n\n\n<p>Licensor: HutchMed (China)\u00a0<\/p>\n\n\n\n<p>Licensee (Buyer): Takeda (Japan)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule, Oral<\/p>\n\n\n\n<p>Asset Target: VEGFR1\/2\/3 Tyrosine Kinase Inhibitor<\/p>\n\n\n\n<p>Potential Indication: Refractory Metastatic Colorectal Cancer<\/p>\n\n\n\n<p>Current Stage: Fruquintinib, approved in China in 2018; With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Takeda will receive an exclusive worldwide license to develop and commercialize fruquintinib in all indications and territories outside of mainland China, Hong Kong and Macau.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$400 million,<\/p>\n\n\n\n<p>Milestone payments up to $730 million.<\/p>\n\n\n\n<p>Royalties on net sales.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/takeda-to-acquire-exclusive-worldwide-ex-china-license-of-hutchmeds-fruquintinib-a-highly-selective-oral-vegfr123-tyrosine-kinase-inhibitor\/\">Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED\u2019s Fruquintinib, a Highly Selective, Oral VEGFR1\/2\/3 Tyrosine Kinase Inhibitor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-01-23 (January 23, 2023) Asset Name: Fruquintinib Licensor: HutchMed (China)\u00a0 Licensee (Buyer): Takeda (Japan) &hellip; <a title=\"[China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI\u00a0Fruquintinib\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/135.html\"><span class=\"screen-reader-text\">[China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI\u00a0Fruquintinib<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-135","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=135"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/135\/revisions"}],"predecessor-version":[{"id":136,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/135\/revisions\/136"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}